Jorth, P., Manuel, C., McLemore, T., Humphries, R. M., Cole, N. C., Schuetz, A. N., Garica, D., Maldonado, M., Rivero, N., Milesi Galdino, A. C., Celedonio, D., LiPuma, J. J., Green, D. A., Zlosnik, J. E. A., Traczewski, M., & Huse, H. K. (2025). Evaluation of antimicrobial susceptibility testing methods for Burkholderia cepacia complex isolates from people with and without cystic fibrosis. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01480-24

Zuckerman, J. B., Hinton, A. C., Lahiri, T., Teneback, C. C., Jia, S., Mermis, J., Polineni, D., Dasenbrook, E., Sadeghi, H., DiMango, E., Dezube, R., West, N. E., Zemanick, E. T., Samya, Z. N., & Gifford, A. H. (2025). C‐Reactive Protein Changes in Adult and Pediatric People With Cystic Fibrosis During Treatment of Pulmonary Exacerbations. Pediatric Pulmonology, 60(1). Portico. https://doi.org/10.1002/ppul.27487

Keating, C., Yonker, L. M., Vermeulen, F., Prais, D., Linnemann, R. W., Trimble, A., Kotsimbos, T., Mermis, J., Braun, A. T., O’Carroll, M., Sutharsan, S., Ramsey, B., Mall, M. A., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Floreth, T., Michelson, P., Sosnay, P. R., … Horsley, A. (2025). Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00411-9

Burdis, N., Milinic, T., Bartlett, L. E., Goss, L., Tallarico, E., Boyle, A., Thaxton, A., Turner, G. A., Benvenuto, L. J., Faro, A., Goss, C. H., Kapnadak, S. G., & Ramos, K. J. (2024). A survey of cystic fibrosis physicians’ views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology, 59(12), 3641–3649. Portico. https://doi.org/10.1002/ppul.27273

Saiman, L., Waters, V., LiPuma, J. J., Hoffman, L. R., Alby, K., Zhang, S. X., Yau, Y. C., Downey, D. G., Sermet-Gaudelus, I., Bouchara, J.-P., Kidd, T. J., Bell, S. C., & Brown, A. W. (2024). Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis. Clinical Microbiology Reviews, 37(3). https://doi.org/10.1128/cmr.00215-21

Kay, D. M., Sadeghi, H., Kier, C., Berdella, M., DeCelie‐Germana, J. K., Soultan, Z. N., Goetz, D. M., Caggana, M., Fortner, C. N., Giusti, R., Kaslovsky, R., Stevens, C., Voter, K., Welter, J. J., & Langfelder‐Schwind, E. (2024). Genetic counseling access and service delivery in New York State is variable for parents of infants with complex CFTR genotypes conferring uncertain phenotypes. Pediatric Pulmonology, 59(7), 1952–1961. Portico. https://doi.org/10.1002/ppul.27023

Rose, N. R., Chalamalla, A. R., Garcia, B. A., Krick, S., Bergeron, J., Sadeghi, H., Schellhase, D. E., Ryan, K. J., Dowell, A. E., Acosta, E. P., & Guimbellot, J. S. (2024). Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulmonary Pharmacology & Therapeutics, 86, 102301. https://doi.org/10.1016/j.pupt.2024.102301

McDonald, C. M., Reid, E. K., Pohl, J. F., Yuzyuk, T. K., Padula, L. M., Vavrina, K., & Altman, K. (2024). Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy. Nutrition in Clinical Practice, 39(S1). Portico. https://doi.org/10.1002/ncp.11122

Miller, J. E., Taylor‐Cousar, J. L., Overdevest, J. B., Khatiwada, A., Mace, J. C., Alt, J. A., Bodner, T. E., Chowdhury, N. I., DiMango, E. A., Eshaghian, P. H., Getz, A. E., Gudis, D. A., Han, E. J., Hwang, P. H., Keating, C. L., Khanwalkar, A., Kimple, A. J., Lee, J. T., Li, D., … Beswick, D. M. (2023). Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. International Forum of Allergy & Rhinology, 14(6), 1079–1087. Portico. https://doi.org/10.1002/alr.23312

Tervo, J. P., DiMango, E., Gudis, D. A., Keating, C., Zhang, Y., Leu, C., Altman, K., Vilarello, B., Jacobson, P., & Overdevest, J. B. (2023). Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy. International Forum of Allergy & Rhinology, 13(12), 2165–2171. Portico. https://doi.org/10.1002/alr.23209

List, R., Solomon, G., Bichl, S., Horton, B. J., Shen, S., Corcoran, B., Sadeghi, H., Britto, M. T., Ren, C., & Albon, D. (2023). Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative. BMJ Open Quality, 12(4), e002466. https://doi.org/10.1136/bmjoq-2023-002466

Shah, K. S., Saiman, L., LiPuma, J. J., Kosorok, M. R., & Muhlebach, M. S. (2024). Association of Pseudomonas aeruginosa incident infections with adherence to cystic fibrosis foundation care guidelines. Journal of Cystic Fibrosis, 23(2), 300–305. https://doi.org/10.1016/j.jcf.2023.10.015

Melton, K., Liu, J., Sadeghi, H., George, M., & Smaldone, A. (2024). Predictors of Transition Outcomes in Cystic Fibrosis: Analysis of National Patient Registry and CF RISE (Responsibility. Independence. Self-care. Education) Data. The Journal of Pediatrics, 265, 113812. https://doi.org/10.1016/j.jpeds.2023.113812

Sabharwal, S., & Lusman, S. S. (2023). CFTR Modulators for the Gastroenterologist. Journal of Pediatric Gastroenterology & Nutrition, 77(4), 445–447. https://doi.org/10.1097/mpg.0000000000003904

Mayer-Hamblett, N., Clancy, J. P., Jain, R., Donaldson, S. H., Fajac, I., Goss, C. H., Polineni, D., Ratjen, F., Quon, B. S., Zemanick, E. T., Bell, S. C., Davies, J. C., Jain, M., Konstan, M. W., Kerper, N. R., LaRosa, T., Mall, M. A., McKone, E., Pearson, K., … Downey, D. G. (2023). Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. The Lancet Respiratory Medicine, 11(10), 932–944. https://doi.org/10.1016/s2213-2600(23)00297-7

Lusman, S. S. (2023). Update on Cystic Fibrosis in Pediatric Patients. Current Gastroenterology Reports, 25(11), 308–315. https://doi.org/10.1007/s11894-023-00896-3

Leonard, A., Bailey, J., Bruce, A., Jia, S., Stein, A., Fulton, J., Helmick, M., Litvin, M., Patel, A., Powers, K. E., Reid, E., Sankararaman, S., Clemm, C., Reno, K., Hempstead, S. E., & DiMango, E. (2023). Nutritional considerations for a new era: A CF foundation position paper. Journal of Cystic Fibrosis, 22(5), 788–795. https://doi.org/10.1016/j.jcf.2023.05.010

Gifford, A. H., Hinton, A. C., Jia, S., Nasr, S. Z., Mermis, J. D., Lahiri, T., Zemanick, E. T., Teneback, C. C., Flume, P. A., DiMango, E. A., Sadeghi, H., Polineni, D., Dezube, R. H., West, N. E., Dasenbrook, E. C., Lucas, F. L., & Zuckerman, J. B. (2023). Complications and Practice Variation in the Use of Peripherally Inserted Central Venous Catheters in People With Cystic Fibrosis. CHEST, 164(3), 614–624. https://doi.org/10.1016/j.chest.2023.03.043

South, K., Smaldone, A., Sadeghi, H., Piane, V., Kowal, R., Wei, L., & George, M. (2023). Parent and adolescent perceptions of cystic fibrosis management responsibility: A mixed‐methods study. Pediatric Pulmonology, 58(8), 2340–2351. Portico. https://doi.org/10.1002/ppul.26494

Baldwin-Hunter, B. L., Rozenberg, F. D., Annavajhala, M. K., Park, H., DiMango, E. A., Keating, C. L., Uhlemann, A.-C., & Abrams, J. A. (2023). The gut microbiome, short chain fatty acids, and related metabolites in cystic fibrosis patients with and without colonic adenomas. Journal of Cystic Fibrosis, 22(4), 738–744. https://doi.org/10.1016/j.jcf.2023.01.013

Uluer, A. Z., MacGregor, G., Azevedo, P., Indihar, V., Keating, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Rubenstein, R. C., Taylor-Cousar, J. L., Tullis, E., Yonker, L. M., Chu, C., Lam, A. P., Nair, N., Sosnay, P. R., Tian, S., Van Goor, F., … Wilson, J. (2023). Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. The Lancet Respiratory Medicine, 11(6), 550–562. https://doi.org/10.1016/s2213-2600(22)00504-5

Kass, A. P., Kazmerski, T. M., Bern, E., Sabharwal, S., Leonard, J., Harrison, M., Barnico, K., Richmond, T., & Sawicki, G. S. (2023). Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis. Journal of Cystic Fibrosis, 22(3), 431–435. https://doi.org/10.1016/j.jcf.2022.11.006

Altamimi, E., Rabab’h, O., Aburizeg, D., Akasheh, L., Dardas, Z., Srour, L., Awad, H., & Azab, B. (2022). Investigating the genetic profile of familial atypical cystic fibrosis patients (DeltaF508-CFTR) with neonatal biliary atresia. Journal of Applied Genetics, 64(1), 71–80. https://doi.org/10.1007/s13353-022-00729-5

Mulinda, C., Yang, N., & Gudis, D. A. (2023). Pediatric Unified Airway. Otolaryngologic Clinics of North America, 56(1), 137–146. https://doi.org/10.1016/j.otc.2022.09.010

Knotts, R. M., Jin, Z., Doyle, J. B., Keating, C., DiMango, E., & Abrams, J. A. (2022). Body mass index and additional risk factors for cancer in adults with cystic fibrosis. Cancer Causes & Control, 33(12), 1445–1451. https://doi.org/10.1007/s10552-022-01635-1

Wilson, A., Altman, K., Schindler, T., & Schwarzenberg, S. J. (2022). Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era. Clinics in Chest Medicine, 43(4), 727–742. https://doi.org/10.1016/j.ccm.2022.06.012

Caverly, L. J., Riquelme, S. A., & Hisert, K. B. (2022). The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation. Clinics in Chest Medicine, 43(4), 647–665. https://doi.org/10.1016/j.ccm.2022.06.007

Kass, A. P., Berbert, L., Dahlberg, S., Bern, E., Sabharwal, S., Leonard, J., Richmond, T., & Sawicki, G. S. (2022). Eating disorders in adolescents and young adults with cystic fibrosis. Pediatric Pulmonology, 57(11), 2791–2797. Portico. https://doi.org/10.1002/ppul.26102

Schmidt, C. N., Friedman, A. M., DiMango, E. A., Linder, A. H., Sobhani, N. C., D’Alton, M. E., & Wen, T. (2022). Trends in and Outcomes of Deliveries Complicated by Cystic Fibrosis. Obstetrics & Gynecology, 140(5), 861–868. https://doi.org/10.1097/aog.0000000000004959

Pinezich, M. R., Tamargo, M. A., Fleischer, S., Reimer, J. A., Hudock, M. R., Hozain, A. E., Kaslow, S. R., Tipograf, Y., Soni, R. K., Gavaudan, O. P., Guenthart, B. A., Marboe, C. C., Bacchetta, M., O’Neill, J. D., Dorrello, N. V., & Vunjak-Novakovic, G. (2022). Pathological remodeling of distal lung matrix in end-stage cystic fibrosis patients. Journal of Cystic Fibrosis, 21(6), 1027–1035. https://doi.org/10.1016/j.jcf.2022.04.016

Stoudemire, W., Jiang, X., Zhou, J. J., Kosorok, M. R., Saiman, L., & Muhlebach, M. S. (2022). Predicting risk-adjusted incidence rates of methicillin-resistant Staphylococcus Aureus and Pseudomonas Aeruginosa in cystic fibrosis programs in the United States. Journal of Cystic Fibrosis, 21(6), 1013–1019. https://doi.org/10.1016/j.jcf.2022.08.002

Lloyd, E. C., Cogen, J. D., Maples, H., Bell, S. C., & Saiman, L. (2022). Antimicrobial Stewardship in Cystic Fibrosis. Journal of the Pediatric Infectious Diseases Society, 11(Supplement_2), S53–S61. https://doi.org/10.1093/jpids/piac071

Spielman, D. B., Beswick, D. M., Kimple, A. J., Senior, B. A., Aanaes, K., Woodworth, B. A., Schlosser, R. J., Lee, S., Cho, D., Adappa, N. D., DiMango, E., & Gudis, D. A. (2022). The management of cystic fibrosis chronic rhinosinusitis: An evidenced‐based review with recommendations. International Forum of Allergy & Rhinology, 12(9), 1148–1183. Portico. https://doi.org/10.1002/alr.22953

Kimple, A. J., Senior, B. A., Naureckas, E. T., Gudis, D. A., Meyer, T., Hempstead, S. E., Resnick, H. E., Albon, D., Barfield, W., Benoit, M. M., Beswick, D. M., Callard, E., Cofer, S., Downer, V., Elson, E. C., Garinis, A., Halderman, A., Hamburger, L., Helmick, M., … Lee, S. E. (2022). Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. International Forum of Allergy & Rhinology, 12(9), 1089–1103. Portico. https://doi.org/10.1002/alr.22974

Stick, S. M., Foti, A., Ware, R. S., Tiddens, H. A. W. M., Clements, B. S., Armstrong, D. S., Selvadurai, H., Tai, A., Cooper, P. J., Byrnes, C. A., Belessis, Y., Wainwright, C., Jaffe, A., Robinson, P., Saiman, L., & Sly, P. D. (2022). The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. The Lancet Respiratory Medicine, 10(8), 776–784. https://doi.org/10.1016/s2213-2600(22)00165-5

Murray, L., & Saiman, L. (2022). Potential opportunities and challenges for infection prevention and control for cystic fibrosis in the modern era. Current Opinion in Infectious Diseases, 35(4), 346–352. https://doi.org/10.1097/qco.0000000000000847

South, K., George, M., Sadeghi, H., Piane, V., & Smaldone, A. (2022). Moving up: Healthcare transition experiences of adolescents and young adults with cystic fibrosis. Journal of Pediatric Nursing, 65, 116–123. https://doi.org/10.1016/j.pedn.2022.03.007

Simonson, J. L., Esposito, C., Frantzen, T., Henthorne, K., Espinal, A., Romano, S., Ramdeo, R., Trentacoste, J., Tsang, D., LaVecchia, G., Abdullah, R., Berdella, M., Bonitz, L., Condos, R., Constantinescu, A., DeCelie-Germana, J. K., DiMango, E., Draine, M., Gimeli, T., … Wang, J. (2022). The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York. Journal of Cystic Fibrosis, 21(3), e176–e183. https://doi.org/10.1016/j.jcf.2022.02.012

Gross, J. E., Caceres, S., Poch, K., Hasan, N. A., Davidson, R. M., Epperson, L. E., Lipner, E., Vang, C., Honda, J. R., Strand, M., Strong, M., Saiman, L., Prevots, D. R., Olivier, K. N., & Nick, J. A. (2021). Healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (HALT NTM) study: Rationale and study design. PLOS ONE, 16(12), e0261628. https://doi.org/10.1371/journal.pone.0261628